


# A NEW DAWN IN CHRONIC URTICARIA:

Opportunities to Improve Patient Outcomes  
With Modern Diagnostic Principles and  
Innovative Treatments on the Horizon



## Suggested Readings

- Altrichter S, Staubach P, Pasha M, et al. An open-label, proof-of-concept study of lirenlimab for antihistamine-resistant chronic spontaneous and inducible urticaria. *J Allergy Clin Immunol*. 2022;149(5):1683-1690.e7.
- Balp MM, Khalil S, Tian H, Gabriel S, Vietri J, Zuberbier T. Burden of chronic urticaria relative to psoriasis in five European countries. *J Eur Acad Dermatol Venereol*. 2018;32(2):282-290.
- Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D. Benralizumab for Chronic Spontaneous Urticaria. *N Engl J Med*. 2020;383(14):1389-1391.
- Ferrer M. Immunological events in chronic spontaneous urticaria. *Clin Transl Allergy*. 2015;5:30.
- Hide M, Kaplan AP. Concise update on the pathogenesis of chronic spontaneous urticaria (CSU). *J Allergy Clin Immunol*. 2022;150(6):1403-1404.
- Kocaturk E, Saini SS, Rubeiz CJ, Bernstein JA. Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring. *J Allergy Clin Immunol Pract*. 2022;10(12):3099-3116.
- Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. *Nat Rev Dis Primers*. 2022;8(1):61.
- Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. *J Allergy Clin Immunol Pract*. 2019;7(5):1659-1661.e1.
- Maurer M, Berger W, Giménez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. *J Allergy Clin Immunol*. 2022;150(6):1498-1506.e2.
- Maurer M, Casale TB, Saini SS, et al. Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A). *J Allergy Clin Immunol*. 2022;149(2):AB312.
- Maurer M, Costa C, Gimenez Arnau A, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. *Clin Exp Allergy*. 2020;50(10):1166-1175.
- Maurer M, Houghton K, Costa C, et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. *World Allergy Organ J*. 2018;11(1):32.
- Mendes-Bastos P, Brasileiro A, Kolkhir P, et al. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions. *Allergy*. 2022;77(8):2355-2366.
- Metz M, Altrichter S, Buttgerit T, et al. The Diagnostic Workup in Chronic Spontaneous Urticaria-What to Test and Why. *J Allergy Clin Immunol Pract*. 2021;9(6):2274-2283.
- Sánchez J, Zakzuk J, Cardona R. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria. *J Allergy Clin Immunol Pract*. 2018;6(1):177-182.e1.
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA<sup>2</sup>LEN/ EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy*. 2022;77(3):734-766.